International COVID 19 Johnson & Johnson moves to buoy investors over paused Covid vaccine trial

Johnson & Johnson moves to buoy investors over paused Covid vaccine trial

The company is one of several working on a vaccine, but on Monday it announced the unexplained illness, closing enrollment for the 60,000-patient trial while an independent patient safety committee is convened.

Author

Date

Category

- Advertisement -

US pharmaceutical giant Johnson & Johnson sought Tuesday to reassure investors after its stock slumped on an announcement that it was pausing a Covid-19 vaccine trial over a sick participant.

The company is one of several working on a vaccine, but on Monday it announced the unexplained illness, closing enrollment for the 60,000-patient trial while an independent patient safety committee is convened.

The announcement sent shares tumbling 2.3 percent at the close of trading Tuesday, even as the company reported healthy third-quarter results, with sales growing 1.7 percent to $21.08 billion.

In a conference call earlier in the day, J&J’s global research head Mathai Mammen said “our plan is to continue the study” following “a temporary pause” caused by the illness.

- Advertisement -

“It’s not at all unusual for unexpected illnesses (to occur) in large studies over their duration. In some cases, serious adverse events… may have something or nothing to do with the drug or vaccine being investigated,” he said.

The Phase 3 trial had started recruiting participants in late September, with a goal of enrolling volunteers across more than 200 US and international locations, the company and the US National Institutes for Health (NIH), which is providing funding, said.

The other countries where the trials were taking place are Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa.

The company’s chief financial officer Joe Wolk said it was unclear whether the participant who became ill was receiving the trial vaccine or the placebo.

“We are waiting for the independent drug safety monitoring board to do their analysis,” he said.

J&J is one of 11 organizations globally to begin a Phase 3 trial on a Covid-19 vaccine.

Washington has given the multinational about $1.45 billion in funding under Operation Warp Speed.

The vaccine is based on a single dose of a cold-causing adenovirus, modified so that it can no longer replicate, combined with a part of the new coronavirus called the spike protein that it uses to invade human cells.

vmt/lo/dax/cs/ft

© Agence France-Presse

/AFP

Follow us on Social Media

Send in your scoops to news@theindependent.sg 

- Advertisement -

Ngee Ann Poly student accused of robbing woman at knifepoint 

Singapore—A Ngee Ann Polytechnic student, then 17 years old, was accused of robbing a woman at knifepoint in Lengkong Tiga last year. He was able to get $40 from her during the robbery. The incident occurred at about 1 am on Oct 3,...

Heng Swee Keat steps aside as leader of the PAP’s 4G team after doubts over ‘am I the right person?’

Singapore -- In a letter to Prime Minister Lee Hsien Loong on Thursday (Apr 8), Deputy Prime Minister (DPM) Heng Swee Keat announced his decision to step aside as leader of the People's Action Party's fourth-generation (4G) team. This means that Mr...

Yee Jenn Jong says the volunteers doing food distribution “simply want to make sure the giving continues”

Singapore -- Celebrating one year of community food distribution, Workers’ Party (WP) politician Yee Jenn Jong says that their journey started “Exactly a year ago, on day 1 of the Circuit Breaker”. In a Facebook post on Wednesday (Apr 7), Mr Yee...
Follow us on Social Media

Send in your scoops to news@theindependent.sg 

Theindependent